Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus - PubMed
6 hours ago
- #Urothelial Carcinoma
- #Avelumab Maintenance
- #Diabetes and Cancer
- Avelumab first-line maintenance improves overall survival in advanced urothelial carcinoma patients with diabetes mellitus.
- Patients with high BMI (≥30 kg/m²) showed a trend towards improved survival with avelumab maintenance.
- The safety profile of avelumab in patients with high BMI or diabetes aligns with the overall trial population.
- Exploratory analyses support avelumab maintenance in patients with high BMI or diabetes following platinum-based chemotherapy.